An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...

This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

RAS mutations are among the most common drivers in cancer, particularly in pancreatic, colorectal, and lung tumors. Despite that, directly targeting RAS proteins proved extremely difficult for years, ...

Applications can be submitted anytime (24/7) through online portal at www.eservices.hec.gov.pk. In case of new user, you need to create an account by selecting the “Sign-up” option, while existing ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...

BCEAO launches CEMSTRAT banking programmes with COFEB and HEC Paris AI boosts banking efficiency but increases cybersecurity risks, experts warn Banks urged to adopt AI with strong cybersecurity and ...

Lasting damage to Ras Laffan Industrial City, the world’s largest liquefied natural gas export plant, would have big consequences for the global energy market. By Raja Abdulrahim Reporting from Dubai ...

A US Navy Global Autonomous Reconnaissance Craft (GARC) maneuvers in the Atlantic Ocean during UNITAS 2025 on Sept. 23, 2025. US Navy photo ARLINGTON, Va. — A new office consolidating the development ...

SOUTH KINGSTOWN, R.I. (WPRI) — Resident advisors are already on campus at the University of Rhode Island (URI) as they prepare for the return of their fellow classmates. While the early return to ...